MDL Achieves CNAS Accreditation, Enhancing Global RegulatorySupport for Preclinical Studies

On June 30, 2025, MDL officially obtained accreditation from the China National Accreditation Service for Conformity Assessment (CNAS), marking a significant milestone in its quality management system and laboratory capabilities.

CNAS is China’s national accreditation body and a signatory of the ILAC Mutual Recognition Arrangement (ILAC-MRA). This accreditation confirms that MDL operates in accordance with internationally recognized standards, ensuring the reliability, consistency, and global acceptance of its testing data.

What This Means for Clients

With CNAS accreditation, MDL is better positioned to support global pharmaceutical and medical device companies by:

• Ensuring data accuracy, traceability, and reproducibility
• Supporting regulatory submissions across multiple jurisdictions
• Aligning with international laboratory standards (ISO/IEC 17025)
• Strengthening quality management and compliance systems

Expanded Testing Capabilities

MDL operates a 33,000 m² integrated laboratory facility, offering a comprehensive range of preclinical evaluation services, including:

• Biocompatibility testing
• Carcinogenicity studies
• Genetic toxicology
• Reproductive and developmental toxicology

These capabilities support a wide range of drug and medical device development programs.

Toprion’s Role

As MDL’s international partner, Toprion provides overseas clients with direct access to CNASaccredited laboratory services. We ensure efficient communication, project coordination, and reliable delivery for global collaborations.

Looking Ahead

This accreditation reflects MDL’s ongoing commitment to delivering high-quality, compliant preclinical services aligned with global standards.